Abdullah Özgür YENİOVA, Mustafa Salih AKIN, Osman DEMİR

Non-invasive prediction of fibrosis in chronic hepatitis B

Aim: To date, the main diagnostic tool for assessing the liver fibrosis stage has been liver biopsy. Despite the advantages in patient prognosis prediction and disease management, the application of liver biopsy is hampered by its limitations. The limitations of liver biopsy have led to a need for the development of a non- invasive scoring system that is simple to use, reliable, and cheap. The aim of this study was to evaluate the accuracy of APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis-4) scores in the prediction of liver fibrosis in Chronic Hepatitis B patients.Material and Methods: A retrospective assessment was made of the electronic medical records to identify patients who underwent liver biopsy for evaluation of fibrosis related to CHB (Chronic Hepatitis B). A total of 352 patients were included in the study. Laboratory parameters that were measured within 7 days of the liver biopsy day were considered suitable for the calculation of the formulae. The APRI and FIB-4 scores was calculated. Liver biopsy reports, which were eligible for inclusion in the study, were assessed retrospectively. The fibrosis stage and histological acitvity index were used as previously described by Ishak. Analyses were performed using SPSS 22 (IBM SPSS Statistics 22, SPSS inc., an IBM Co., Somers, NY).Results: APRI was well correlated with fibrosis and HAI score (r=0.280, p

PDF

___

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Lok AS, Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol 2009;33:911-5.
3. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
4. Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009;49:22-7.
5. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
6. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
7. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
8. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
9. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
10. Regev A, Berho M, Jeffers LJ. et al., Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
11. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-8.
12. Cassinotto C, Lapuyade B, Aït-Ali A et al. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography-comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology 2013;269:283-92.
13. Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol 2013;25:428-34.
14. Chen B, Ye B, Zhang J, et al. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 2013;8:e68780.
15. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
16. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al, Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451-9.
17. Adams ST, Leveson SH. Clinical prediction rules. BMJ 2012;344:8312.
18. Lin CL, Liu CH, Wang CC, et al. Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B. J Clin Gastroenterol 2015;49:705-13.
19. Li J, Gordon SC, Rupp LB, et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat 2014;21:930-7.
20. Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25:1076-81.
21. Erdogan S, Dogan HO, Sezer S, et al. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest 2013;73:300-8.
22. Wang F, Gatsonis CA. Hierarchical models for ROC curve summary measures: design and analysis of multi-reader, multi-modality studies of medical tests. Stat Med 2008;27:243-56.
23. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015;61:292-302.